Eli Lilly and Company
BISPECIFIC ANTIBODIES TARGETING IMMUNE CHECKPOINTS
Last updated:
Abstract:
The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
Status:
Application
Type:
Utility
Filling date:
12 Jul 2019
Issue date:
23 Sep 2021